Working... Menu

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism (REVERSEII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00967304
Recruitment Status : Completed
First Posted : August 27, 2009
Last Update Posted : September 1, 2016
Centre Hospitalier Régional et Universitaire de Brest
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
The main objective of this study is to verify whether a new clinical decision rule identifying patients diagnosed with unprovoked blood clots who have a low risk of recurrence can safely stop oral anticoagulant therapy after 5-7 months of treatment.

Condition or disease Intervention/treatment Phase
Idiopathic Venous Thromboembolism Other: Application of the"Men continue and HER DOO2" rule Phase 4

Detailed Description:

Up to 50% of patients with a first episode of venous thromboembolism (VTE) have no identifiable cause (i.e. are unprovoked VTEs). The risk of recurrent VTE in this large group of patients with unprovoked VTE after 3-6 months of anticoagulant therapy is 5-10.8% in the year following discontinuation of oral anticoagulant therapy. One in six to one in twenty recurrences of a new VTE are fatal. Given the intermediate risks of recurrence in unselected unprovoked VTE patients, clinicians do not have clear guidance on whether to continue or discontinue anticoagulants in patients with unprovoked VTE. Recently attention has turned to the concept of risk stratification to identify subgroups of patients with unprovoked VTE who could safely discontinue oral anticoagulation therapy (OAT).

In the REVERSE I study, a clinical decision rule derivation study conducted from 2001 to 2006, we developed and internally validated the clinical decision rule "Men continue and HER DOO2" that identifies patients with a first unprovoked VTE who likely have a low risk of recurrent VTE and could safely discontinue OAT subsequent to 5-7 months of OAT. The present study will evaluate if the "Men continue and HER DOO2" rule (comprised of gender, elevated D-dimer levels, post-thrombotic signs, obesity, and older age) is safe, clinically useful, and reproducible when prospectively implemented in multiple centers and a variety of settings. If this clinical decision rule is validated, it will provide physicians with important information to allow them to more confidently identify unprovoked VTE patients at low risk of VTE recurrence who may not need to continue OAT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2779 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: REVERSEII: Validation of the "Men and HERDOO2"- A Clinical Decision Rule to Identify Patients With "Unprovoked" Venous Thromboembolism Who Can Discontinue Anticoagulants After 6 Months of Treatment.
Study Start Date : November 2008
Actual Primary Completion Date : January 2015
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: 1 Discontinue OAT or AAA

Patients classified as being at low risk of recurrent VTE by the "HER DOO2"rule.

If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding.

Other: Application of the"Men continue and HER DOO2" rule

Consecutive patients will have the"Men continue and HER DOO2" rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.

"Men continue and HER DOO2" rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years.

Other Name: Clinical Decision Rule

No Intervention: 2 Observation arm

Men and patients classified as being at high risk of recurrent VTE by the "HER DOO2"rule.

If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding.

Primary Outcome Measures :
  1. The primary study outcome is the incidence of adjudicated recurrent major VTE at 1 year in patients deemed by the "Men and HER DOO2" CDR to be at low risk of recurrent VTE. [ Time Frame: One year ]

Secondary Outcome Measures :
  1. Any VTE 1 year event rate in low risk patients [ Time Frame: One year ]
  2. Major bleeding 1 year event rate in un-anticoagulated low risk patients [ Time Frame: One year ]
  3. Major VTE 1 year event rate in high risk patients who continue anticoagulant therapy [ Time Frame: One year ]
  4. Major VTE 1 year event rate in high risk patients who discontinue anticoagulant therapy [ Time Frame: One year ]
  5. Major Bleeding 1 year event rate in high risk patients [ Time Frame: One year ]
  6. Clinical utility of the rule [ Time Frame: One year ]
  7. Inter-observer reliability of the clinical decision rule [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First episode of major unprovoked VTE
  • VTE objectively proven
  • VTE treated for 5-12 months with anticoagulant therapy authorized for the REVERSE II study (initial or ongoing therapy)
  • Absence of recurrent VTE during the treatment period

Exclusion Criteria:

  • Less than 18 years of age
  • Patients who have already discontinued anticoagulant therapy
  • Patients requiring ongoing anticoagulation for reasons other than VTE
  • Being treated for a recurrent unprovoked VTE
  • Patients with high risk thrombophilia
  • patients who plan on using exogenous estrogen(OCP,HRT)if anticoagulant therapy is discontinued
  • Patients with pregnancy associated VTE
  • Geographically inaccessible for follow-up
  • Patients unable or unwilling to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00967304

Layout table for location information
United States, California
UC Davis
Santa Monica, California, United States
United States, Maine
Penobscot Bay Medical Center
Rockport, Maine, United States
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
Australia, New South Wales
Prince of Wales Hospital
Sydney, New South Wales, Australia
CUB Hopital Erasme
Brussels, Belgium
Canada, Nova Scotia
CDHA-Queen Elizabeth II Health Science Centre
Halifax, Nova Scotia, Canada, B3H2Y9
Canada, Ontario
Hamilton Health Sciences Center
Hamilton, Ontario, Canada
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
Victoria Hospital
London, Ontario, Canada, N6A 4G5
Ottawa Health Research Institute
Ottawa, Ontario, Canada, K1Y 4E9
University Health Network
Toronto, Ontario, Canada
Canada, Quebec
SMBD Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Hopital Sacre Coeur
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
St. Mary's Hospital - CHUM
Montreal, Quebec, Canada
Canada, Saskatchewan
Saskatchewan Drug Research Institute
Saskatoon, Saskatchewan, Canada, S7N 0W8
Hopital Enfant Jesus
Quebec, Canada
Centre Hospitalier Regional Universitaire de Brest
Brest, France
Orange Lifesciences
Nirmaya, India
Sahyadri Speciality Hospital
Pune, India
Shefali Centre
Shefali, India
Jashvant Patel Clinic
Surat, India
Hopitaux Universitaires de Geneve
Geneva, Switzerland
Sponsors and Collaborators
Ottawa Hospital Research Institute
Centre Hospitalier Régional et Universitaire de Brest
Layout table for investigator information
Study Chair: Marc Rodger, MD, MSc Ottawa Hospital Research Institute

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ottawa Hospital Research Institute Identifier: NCT00967304     History of Changes
Other Study ID Numbers: 2008039-01H
First Posted: August 27, 2009    Key Record Dates
Last Update Posted: September 1, 2016
Last Verified: August 2016

Keywords provided by Ottawa Hospital Research Institute:
Unprovoked Venous thromboembolism
Clinical decision rule
Risk stratification

Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases